MRNA Dana dhuwit perusahaan Moderna

Tandha merek Moderna Corp (MRNA)

Declining demand for COVID-19 vaccines creates risks, yet the potential of oncology vaccines and RSV provides growth for Moderna, Inc. (MRNA). This mRNA pioneer programs cells to fight cancer, while AI-driven synthesis robotics accelerate the launch of trials. The cash position demonstrates support, where the value of 5.15 is the current figure, confirming management's ability to fund expansion and development.

Cadangan dhuwit perusahaan: Moderna Inc (MRNA) kanggo 04.07.2022 - 21.11.2026

Ringkesan rincian data analitis Moderna Inc (MRNA)

- nilai saham lan prakiraan konsensus rega:
Pambiji fundamental:MRNA Moderna
Produk merek Moderna

This indicator captures the volume of liquid assets available to promptly cover short-term liabilities without resorting to external borrowing. The trend is driven by the difference between operating cash flow and capital expenditures. By analyzing current cash reserves, an investor assesses the business's financial stability. For Moderna, Inc. (MRNA), such reserves are critical, as they ensure the funding of costly R&D and the retention of high-paid genetics specialists.